The FDA only approved this enzyme injection for the butt, but doctors often use it on the thighs too — with a weaker solution and different injection pattern.
Scientific Claim
CCH-aaes is currently FDA-approved only for cellulite on the buttocks, but clinicians commonly use it off-label for the thighs using different dilution and injection techniques.
Original Statement
“While on-label use of CCH-aaes is currently restricted to cellulite on the buttocks, the discussion also included off-label treatment of the thighs... a different injection technique was identified as optimal for injection in the thigh (Figure 1B)...”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This is a factual statement about regulatory status and clinical practice patterns, not a claim of efficacy. It is accurately and appropriately stated as observed reality.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Prospective Cohort StudyLevel 2bThe prevalence and outcomes of off-label CCH-aaes use for thigh cellulite in real-world clinical practice.
The prevalence and outcomes of off-label CCH-aaes use for thigh cellulite in real-world clinical practice.
What This Would Prove
The prevalence and outcomes of off-label CCH-aaes use for thigh cellulite in real-world clinical practice.
Ideal Study Design
A prospective multicenter registry of 500 patients receiving CCH-aaes for thigh cellulite (off-label), with standardized documentation of dilution, injection technique, CR-PCSS/PR-PCSS scores, and adverse events at 12 and 24 weeks.
Limitation: Cannot establish efficacy relative to placebo or compare to on-label use.
Randomized Controlled TrialLevel 1aThat off-label CCH-aaes use on thighs is non-inferior to on-label use on buttocks in terms of efficacy and safety.
That off-label CCH-aaes use on thighs is non-inferior to on-label use on buttocks in terms of efficacy and safety.
What This Would Prove
That off-label CCH-aaes use on thighs is non-inferior to on-label use on buttocks in terms of efficacy and safety.
Ideal Study Design
A double-blind RCT comparing 3 sessions of CCH-aaes (0.23 mg/mL, 3-aliquot) for buttocks vs. (0.046 mg/mL, 5-aliquot) for thighs in 200 women, with primary outcome: CR-PCSS improvement at 12 weeks and secondary: bruising, pain, and antibody response.
Limitation: Ethical and logistical barriers to blinding in off-label use.
Cross-Sectional SurveyLevel 4The proportion of clinicians using CCH-aaes off-label for thighs and their adherence to recommended techniques.
The proportion of clinicians using CCH-aaes off-label for thighs and their adherence to recommended techniques.
What This Would Prove
The proportion of clinicians using CCH-aaes off-label for thighs and their adherence to recommended techniques.
Ideal Study Design
A national survey of 300+ aesthetic practitioners using CCH-aaes, asking about frequency of off-label thigh use, dilution protocols, injection patterns, and awareness of FDA labeling.
Limitation: Self-report bias and inability to assess patient outcomes.
Evidence from Studies
Supporting (1)
The study shows that doctors are already using this FDA-approved butt cellulite treatment on thighs too, using different methods — which is exactly what the claim says.